Denali Capital Acquisition Corp. Class A
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch DNQAF and buy or sell other stocks, ETFs, and their options commission-free!About DNQAF
Semnur Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative non-opioid pain management products for the treatment of acute and chronic pain. Its lead product candidate, SP-102, is a non-opioid novel injectable corticosteroid gel formulation for patients with moderate to severe lumbosacral radicular pain.
CEOJaisim Shah, MBA
CEOJaisim Shah, MBA
Employees2
Employees2
HeadquartersPalo Alto, California
HeadquartersPalo Alto, California
Founded
Founded
Employees2
Employees2
DNQAF Key Statistics
Market cap2.77B
Market cap2.77B
Price-Earnings ratio-7.43
Price-Earnings ratio-7.43
Dividend yield—
Dividend yield—
Average volume—
Average volume—
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$20.00
52 Week high$20.00
52 Week low$9.00
52 Week low$9.00
Stock Snapshot
With a market cap of 2.77B, Denali Capital Acquisition Corp. Class A(DNQAF) trades at $12.05. The stock has a price-to-earnings ratio of -7.43.
Denali Capital Acquisition Corp. Class A(DNQAF) stock opened on 2025-12-12 at —. The price climbed to — and dipped to —.
Denali Capital Acquisition Corp. Class A(DNQAF) shares are trading with a volume of 0.
During the past year, Denali Capital Acquisition Corp. Class A(DNQAF) stock moved between $9.00 at its lowest and $20.00 at its peak.
During the past year, Denali Capital Acquisition Corp. Class A(DNQAF) stock moved between $9.00 at its lowest and $20.00 at its peak.
People also own
Based on the portfolios of people who own DNQAF. This list is generated using Robinhood data, and it’s not a recommendation.